Previous Close | 0.0051 |
Open | 0.0052 |
Bid | 0.0050 x 0 |
Ask | 0.0054 x 0 |
Day's Range | 0.0050 - 0.0052 |
52 Week Range | 0.0030 - 0.0160 |
Volume | |
Avg. Volume | 1,652,856 |
Market Cap | 6.169M |
Beta (5Y Monthly) | -0.40 |
PE Ratio (TTM) | 0.04 |
EPS (TTM) | 0.1400 |
Earnings Date | Dec 16, 2024 - Dec 31, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves. Financial Highlights for Q2 2024: Revenue: ViaDerma maintained steady revenues of $300,191 for the
A second shipment of 500,000 units is expected to be made by the end of OctoberLOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to announce the successful completion of its first shipment of 500,000 units of its flagship product, a tetracycline based topical antibiotic to Nigeria. The shipment was sent out as planned before the end of August 2024. This miles